中文名称: | OR-1896 | ||||
---|---|---|---|---|---|
英文名称: | OR-1896 | ||||
别名: | ( - )-α-甲基胺盐酸盐;(R)-N-乙酰基-6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2H)-吡嗪酮;左西孟旦代谢物 (R)-N-ACETYL-6-(4-AMINOPHENYL)-4,5-DIHYDRO-5-METHYL-3(2H)-PYRIDAZINONE | ||||
CAS No: | 220246-81-1 | 分子式: | C13H15N3O2 | 分子量: | 245.28 |
CAS No: | 220246-81-1 | ||||
分子式: | C13H15N3O2 | ||||
分子量: | 245.28 |
基本信息
产品编号: |
O10212 |
||||
产品名称: |
OR-1896 |
||||
CAS: |
220246-81-1 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
分子量: |
245.28 |
-20℃ |
1个月 |
||
化学名: |
(R)-N-ACETYL-6-(4-AMINOPHENYL)-4,5-DIHYDRO-5-METHYL-3(2H)-PYRIDAZINONE |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
|
|||
Ethanol |
|
||||
Water |
|
||||
体内(现配现用): |
|
||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
4.0770mL |
20.3849mL |
40.7697mL |
5mM |
0.8154mL |
4.0770mL |
8.1539mL |
10mM |
0.4077mL |
2.0385mL |
4.0770mL |
生物活性
产品描述 |
一种高选择性磷酸二酯酶(PDE III)抑制剂,是一种功能强大的血管扩张剂。OR-1896可以打开ATP敏感的K+通道,并具有Ca2+致敏作用。 |
||
靶点 |
PDE3/PDE Ⅲ |
K+ Channel |
Drug Metabolite |
体外研究 |
There are many evidences has accumulated and revealed a variety of beneficial pleiotropic effects OR-1896.OR-1896 evokes prominent vasodilatory responses,activation of ATP-sensitive sarcolemmal K+channels of smooth muscle cells appears as a powerful vasodilator mechanism.Additionally,activation of ATP-sensitive K+channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. |
||
体内研究 |
During the metabolism of Levosimendan approximately 5% of the drug is converted to the metabolite OR-1855 in the large intestine,and then acetylated in the liver to form the active metabolite OR-1896.Binding to plasma proteins is 98% for Levosimendan but only 40% for OR-1896.Unlike Levosimendan,which has an elimination half-life of 1-1.5h,the half-life of OR-1896 is about 75 to 80h allowing cardiovascular effects to persist up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan.The pharmacokinetic of the parent drug is unaltered in subjects with severe renal impairment or with moderate hepatic impairment,whereas the elimination of its metabolites (OR-1896) can be prolonged. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )